• Blog Pic 2 photo BlogPic2.jpeg
  • Welcome to Life Science Deal Flow!

    Welcome to the personal blog of Adam Rubenstein. Here read about how an obsessive fascination with Innovation Intelligence can function to accelerate the commercialization of global R&D. And perhaps also some thoughts on poetry, (bio)pharma, cool science, chihuahuas and college football. Visit Collective IP.

Only Got ‘Lil Glucose in My Pathway…

For all you crazy biochem kids and your Krebs Cycle. Enjoy this little diddy.

(For those reading this in email or RSS click HERE to view)

US RepWill be paying close attention to this.

The Technology and Research Accelerating National Security and Future Economic Resiliency Act of 2013 or the TRANSFER Act of 2013 – Amends the Small Business Act to replace provisions requiring the Director of the National Institutes of Health to use funds for a Proof of Concept Partnership pilot program to accelerate the creation of small businesses and the commercialization of research innovations made by certain institutions with provisions directing each federal agency required to establish a small business technology transfer (STTR) program to carry out an Innovative Approaches to Technology Transfer Grant Program to support innovative approaches to technology transfer at institutions of higher education, nonprofit research institutions, and federal laboratories in order to accelerate the commercialization of federally funded research and technology by small businesses.

Innovative approaches to technology transfer:

USE OF FUNDS – Activities supported by grants under this subsection may include -

(I) providing early-stage proof of concept funding for translational research;
(II) identifying research and technologies at recipient institutions that have the potential for accelerated commercialization;
(III) technology maturation funding to support activities such as prototype construction, experiment analysis, product comparison, and collecting performance data;
(IV) technical validations, market research, clarifying intellectual property rights position and strategy, and investigating commercial and business opportunities; and
(V) programs to provide advice, mentoring, entrepreneurial education, project management, and technology and business development expertise to innovators and recipients of technology transfer licenses to maximize commercialization potential.

Latest Major Action: 9/24/2013 Referred to House subcommittee. Status: Referred to the Subcommittee on Research and Technology.

Stay tuned for more details and progress updates

 UW NW PSUUTHSCVANDYThis is an interesting evolution of the traditional genome-wide association study (GWAS), where researchers sleuth for common mutations in the DNA of people with the same condition, a new method, Phenome-wide Association studies (PWAS), reverses the GWS process by beginning with a gene mutation and then scrubs Electronic Medical Records (EMRs) for possible links between the variant and disease.

Published in Nature Biotechnology, researchers from Vanderbilt, Mayo Clinic, University of Washington, Northwestern, Penn State, and the University of Texas Health Science Center contributed to this Proof-of-Concept PWAS where genotype data from 13,835 individuals of European descent, exhibiting 1,358 diseases collectively had 3,144 single-nucleotide polymorphisms (SNP’s) analyzed, checking each SNP’s association with each of the 1,358 disease phenotypes. The authors reported 63 previously unknown SNP-disease associations.

The validation of this EMR-PWAS model may ultimately provide drug developers a new tool, whereby the identification of the genetic causes of disease may illuminate potentially new druggable targets.

Systematic comparison of phenome-wide association study of electronic medical record data and genome-wide association study data

World-Aids-Day-2013 copyAn estimated 34 million people have HIV. More than 25 million people between 1981 and 2007 have died from the virus, making it one of the most destructive pandemics in history.

A newly discovered HIV strain has been identified that leads to significantly faster development of AIDS than current prevalent forms. Read: “Faster Progression to AIDS and AIDS-Related Death Among Seroincident Individuals Infected With Recombinant HIV-1 A3/CRF02_AG Compared With Sub-subtype A3” in the Journal of Infectious Disease. The recombinant studied is called A3/02 and is a cross between the two most common strains in Guinea-Bissau, West Africa – 02AG and A3. The research is based on a unique long-term follow-up of HIV-infected individuals in Guinea-Bissau, a project run by Lund University.

Very satisfying indeed to be able to have announced the close of our Series A financing last week. The press release can be read HERE.

Brief summary Collective IP, Inc., the global leader in innovation intelligence, featuring the world’s most comprehensive and accurate organization of technologies emerging from research institutes and companies, has completed a $2.5 million Series A financing, bringing the total amount raised to date to $3.6 million. The funding was led by High Country Venture with follow-on participation by Techstars founder David Cohen (@davidcohen), and additional individual investors.

“With over one hundred Fortune 500 companies and technology transfer teams participating in the direction of Collective IP, each side of this marketplace is communicating the value of our platform.”

« Previous Entries  Next Page »

to top of page...